These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 29248691)

  • 21. Kratom abuse in Ramathibodi Poison Center, Thailand: a five-year experience.
    Trakulsrichai S; Tongpo A; Sriapha C; Wongvisawakorn S; Rittilert P; Kaojarern S; Wananukul W
    J Psychoactive Drugs; 2013; 45(5):404-8. PubMed ID: 24592666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users.
    Smith KE; Bunting AM; Walker R; Hall MT; Grundmann O; Castillo O
    J Psychoactive Drugs; 2019; 51(4):311-322. PubMed ID: 30961450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of urinary protein profile in regular kratom (
    Jasim RK; Hassan Z; Singh D; Boyer E; Gam LH
    J Addict Dis; 2022; 40(2):235-246. PubMed ID: 34747343
    [No Abstract]   [Full Text] [Related]  

  • 24. Characteristics of deaths associated with kratom use.
    Corkery JM; Streete P; Claridge H; Goodair C; Papanti D; Orsolini L; Schifano F; Sikka K; Körber S; Hendricks A
    J Psychopharmacol; 2019 Sep; 33(9):1102-1123. PubMed ID: 31429622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature.
    Stanciu C; Ahmed S; Gnanasegaram S; Gibson S; Penders T; Grundmann O; McCurdy C
    Am J Drug Alcohol Abuse; 2022 Sep; 48(5):509-528. PubMed ID: 36001875
    [No Abstract]   [Full Text] [Related]  

  • 26. Kratom Dependence and Treatment Options: A Comprehensive Review of the Literature.
    Bin Abdullah MFIL
    Curr Drug Targets; 2020; 21(15):1566-1579. PubMed ID: 32682371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severity of Kratom (Mitragyna speciosa Korth.) Psychological Withdrawal Symptoms.
    Singh D; Narayanan S; Müller CP; Swogger MT; Rahim AA; Leong Bin Abdullah MFI; Vicknasingam BK
    J Psychoactive Drugs; 2018; 50(5):445-450. PubMed ID: 30152738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products.
    Fowble KL; Musah RA
    Forensic Sci Int; 2019 Jun; 299():195-202. PubMed ID: 31059866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.
    Smith KE; Lawson T
    Drug Alcohol Depend; 2017 Nov; 180():340-348. PubMed ID: 28950240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kratom (Mitragyna speciosa): A Case Review of Use Before and During Pregnancy.
    Faucher MA; Morillos S; Cordova P; McNeil-Santiel J; Onisko N; Adhikari EH; Nelson DB
    J Midwifery Womens Health; 2024; 69(1):144-149. PubMed ID: 37679866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.
    Prozialeck WC; Jivan JK; Andurkar SV
    J Am Osteopath Assoc; 2012 Dec; 112(12):792-9. PubMed ID: 23212430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A coincidence of addiction to "Kratom" and severe primary hypothyroidism.
    Sheleg SV; Collins GB
    J Addict Med; 2011 Dec; 5(4):300-1. PubMed ID: 21817918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severity of Pain and Sleep Problems during Kratom (Mitragyna speciosa Korth.) Cessation among Regular Kratom Users.
    Singh D; Narayanan S; Vicknasingam BK; Prozialeck WC; Ramanathan S; Zainal H; Harun SN
    J Psychoactive Drugs; 2018; 50(3):266-274. PubMed ID: 29558272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kratom as a potential substance use disorder harm reduction agent.
    Green M; Vadiei N; Veltri CA; Grundmann O; Evoy KE
    Front Public Health; 2024; 12():1416689. PubMed ID: 38873312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic and clinical assessment of kratom: An update.
    White CM
    Am J Health Syst Pharm; 2019 Nov; 76(23):1915-1925. PubMed ID: 31626272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kratom: Implications for Health Care Providers.
    Goldin D; Salani D; Mckay M
    J Psychosoc Nurs Ment Health Serv; 2019 Dec; 57(12):15-20. PubMed ID: 31774129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.
    Avery BA; Boddu SP; Sharma A; Furr EB; Leon F; Cutler SJ; McCurdy CR
    Planta Med; 2019 Mar; 85(4):340-346. PubMed ID: 30452072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Implications of Kratom (
    Prevete E; Kuypers KPC; Theunissen EL; Esposito G; Ramaekers JG; Pasquini M; Corazza O
    Curr Addict Rep; 2023; 10(2):317-334. PubMed ID: 37266188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature.
    Singh D; Narayanan S; Vicknasingam B
    Brain Res Bull; 2016 Sep; 126(Pt 1):41-46. PubMed ID: 27178014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Use of Benzodiazepines among Kratom (
    Singh D; Narayanan S; Grundmann O; Boyer EW; Vicknasingam B
    J Psychoactive Drugs; 2020; 52(1):86-92. PubMed ID: 31218929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.